The finding of reduced tissue level bone formation early after stroke is in agreement with studies demonstrating that biochemical markers of bone formation were reduced (when compared to controls) in the early phase of stroke recovery [2] and throughout the first year [3] in addition to a marked early increase in resorption markers.
Biochemical markers of bone formation were increased with teriparatide treatment compared with placebo, and BMD and markers of bone formation did not substantially decrease for up to 1 year after discontinuation of teriparatide therapy (Cosman et al 2001).
On the other hand, serum osteocalcin and bone-specific alkaline phosphatase, reflecting bone formation, were increased to a less degree compared to the increase of urinary pyridinoline cross-links, suggesting the imbalance between bone formation and resorption with subsequent bone loss in hyperthyroidism [ 2, 14].
The regenerated bone mineral density (BMD) in the tooth socket, and the mineral apposition rate and the bone formation rate, direct evidences of bone formation, were significantly decreased in the LPS-injected group compared to the PBS-injected group.
Progression of ankylosing enthesitis, in particular chondrocyte hypertrophy and new bone formation, was delayed as compared with wild-type mice.
By contrast, no significant difference in bone formation was observed when PLA/PGA and CPC were compared to autografts.
In response to the second advancement, new bone formation was significantly higher when compared with single advancement with a maximum increase of 50% and 100% in the condyle and glenoid fossa, respectively.
The OVx group with drill hole showed the same effect in response to CAFG treatment but bone formation was significantly less when compared with Sham group.
In particular, the ratio of new bone formation was the highest at 2 weeks compared with the first week and fourth week.
